Cancer‐derived EVs present TGF‐β at their surface as a fully functional complex with type III TFG‐β receptor (also known as heparan sulphate proteoglycan betaglycan) that elicits SMAD‐dependent signalling and induces cellular differentiation in target cells (Webber et al., 2010). The gene discussed is TGFB1; the disease is cancer.